Rukobia

Generic Name: fostemsavir

Drug Class: Entry Inhibitors

Company: ViiV Healthcare

Approval Status: Approved

Generic Version Available: No

Experimental Code: BMS-663068

Drug Indication

Rukobia is approved for use as part of combination treatment for HIV. It is not yet included in the U.S. Department of Health and Human Services (DHHS) Antiretroviral Guidelines for Adults and Adolescents. Rukobia is indicated for treatment-experienced people with drug-resistant HIV. Visit http://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_recommendations.pdf for the full DHHS guidelines.

General Info

Rukobia is in a category of HIV medicines known as attachment inhibitors. It targets a different step of the viral lifecycle and may be an option for indiviuals with HIV that has become resistant to other drugs.

Rukobia was approved in July 2020. It had previously been granted FDA fast track and breakthrough therapy designations, which expedited the development and review of the medication.

Dosage

Adult Dose:

One 600 mg tablet taken orally twice daily.

Pediatric Dose:

N/A

Dosing Info:

Rukobia must be used in combination with other HIV drugs. It can be taken with or without food.

Side Effects

The most common adverse reactions are fatigue, nausea and diarrhea.

Drug Interactions

For an overview of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Rukobia or may require dose adjustments, consult the Rukobia package insert.

Other Info

https://www.poz.com/article/fostemsavir-offers-hope-hiv-treatment-options

---

For More Info: https://www.rukobiahcp.com/

Patient Assistance Program Info: https://www.viivconnect.com/

Last Reviewed: July 2, 2020
